Engineering and viral hepatitis prevention and treatment of human immunodeficiency

Non-antigen-specific immune drugs increases the immune prevention of infectious diseases in this new method, known as the twenty-first century, the human immune engineering research.

The twenty-first century, the body's immune latest research project

As early as 1987, experimental study, we found that in the antigen stimulated levamisole liniment can quickly enhance the body's specific exemption. In rats, horses to prevent filarial infection study, we observed that as long as the skin can be painted levamisole 1-2 times mice and horses to improve the immune response against filarial-specific.

The specific method is: Immunization-treated mice by 10mg/kg levamisole applicator, and in applicator 7 days after infection of larvae per 50 mice were inoculated subcutaneously with a dose of their skin on both sides of the groin. Immunohistochemistry according to three horse / kg subcutaneously worm volume, was inoculated 5 days before 5 days after inoculation respectively 20mg/kg levamisole applicator. Control group, rats and horses do not applicator, according to the amount of the same methods, and insect larvae were inoculated infection.

The results showed that: 56 immunohistochemistry mice, only 4 cases the disease, 18 disease control group, all rats (P <0.001);>

Immunohistochemistry Ma compared with the control group occurred 10 days before Marty protective antibody peak, and the higher antibody concentration by statistical P <0.01.>

This experiment confirmed that, through the non-specific immune liniment levamisole drug, to enhance the body's resistance, when there is antigen (infection of the original invasion or pathogen inoculation), the same as vaccination, but vaccine coverage without the system, to clear the antigen through the stimulation of antigen-specific immune protection obtained, that is no separation of viruses, bacteria system of seedlings, but rather through the application of liniment levamisole administration from time to time quantitative skin by transdermal absorption, improvement, rehabilitation, control the body's immune function, of foreign antigens to inhibit or even eliminate the role of foreign antigen, so that after invasion of pathogens to kill, inhibit, to lose their pathogenicity without causing disease, and the use of foreign antigen-specific immune stimulation to obtain the protection of vaccine coverage can be achieved without the system access to protective immunity against infectious diseases, completely changed the procedures for vaccination against infectious diseases. Non-antigen-specific immune drugs increases the immune prevention of infectious diseases in this new method, known as the twenty-first century, the human immune engineering research.

Results of exploration and practice

Levamisole can improve the body of non-specific immune response of immune cells, such as increasing medium-sized role of granulocyte chemotaxis, increasing the phagocytic function of phagocytes, when the antigen into the body, the immune group of animals have more immune cells more quickly to play a non-specific immunity should play a role in anti-infection without disease.

Followed by levamisole can enhance the activity of lymphocytes, increasing the number of lymphocytes, antigen invasion, can produce a stronger specific immune response, so the immune group is almost no incidence of mice and horses. Research suggests that by improving the body's non-specific immune response, in antigen-stimulated conditions, can enhance the body against the antigen-specific immune response, to gain protective immunity. Through the liniment levamisole enhance immune cell activity can enhance the body's immune response to hepatitis B vaccine-specific, it is possible to reach liniment levamisole synergy with the hepatitis B vaccine.

Results of exploration and practice

The multi-party discussions Kaihua Pharmaceutical Science Alliance, chairman of the world's productivity, the productivity of the world Branch of China Academy of Sciences Academician David Chu-wen, through 12 years of experimental study and effort to invent the BRM third-generation agents - a new type of governance of hepatitis B L Miles liniment. Since 1994, the application of this new approach, multi-year clinical study has confirmed, BRM third-generation agents - Mien Yikang liniment levamisole on the immune regulation - anti-viral treatment of chronic hepatitis B virus infection, efficacy outstanding. Clinical show that levamisole liniment can be blocked by hepatitis B virus mother to child transmission, prevention of pregnant women infected with the virus due to a fever caused by abortion and fetal malformation worry about. It is not only treatable chronic hepatitis B virus infection, blocking hepatitis B virus mother to child transmission, and prevention of hepatitis B caused hepatocellular carcinoma can be changed, method is simple and easy to promote. Experts in China with liver disease has been recommended by the national construction projects, urban development, and well-co-recognition of the General Assembly to grant "national well-focused Recommended Product", being patient as the "know what that reason I agree with" good medicine. In 2000 won the national invention patent (patent No. ZL94103359.7) and the National medicine accurate (national medicine accurate XF20001196) approval number. Researchers at the patent on the patented invention are also further the development of products in order to serve more patients to benefit.